FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
FDA staff have raised data concerns and disputed claims of Phase 3 success for Capricor's DMD cell therapy, deramiocel. This development has led to a significant drop in share price, with reports indicating the stock is on track for its worst day ever.
Coverage from BioSpace, Yahoo Finance, and RTTNews emphasizes the "ugly picture" painted by FDA documents and a divide among analysts regarding the probability of the therapy's approval. Legal scrutiny has also emerged, as the Kehoe Law Firm and Holzer & Holzer, LLC have announced investigations into the company.
Attention now turns to August 2026, when a decision from the FDA is expected.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 14m ago.
Quick answers
What therapy is the FDA questioning?
The FDA is disputing claims of Phase 3 success for deramiocel, a cell therapy for DMD.
How has the market reacted to the news?
Shares of Capricor Therapeutics (CAPR) have plunged, with analysts noting it is on track for its worst day ever.
What legal actions have been initiated?
Both the Kehoe Law Firm, P.C. and Holzer & Holzer, LLC have announced investigations into Capricor Therapeutics.
Coverage (5)
- CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor T The National Law Review · 9h ago
- CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ Yahoo Finance · 9h ago
- Biotech Stocks Facing FDA Decision In August 2026 RTTNews · 9h ago
- CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC GlobeNewswire · 9h ago
- FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy BioSpace · 9h ago
Topics
Related trends
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
Otsuka receives FDA approval for Simtriyo, establishing a new drug class for the treatment of ADHD.
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics shares have declined following the release of mixed Phase 2 trial results for its schizophrenia drug candidate.
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to reports of the medication being subpotent.
Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx is expanding its immunology pipeline with a $2.2 billion acquisition of autoimmune biotech firm Forte Biosciences.
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
Compounded GLP-1 drugs creating concern among doctors and FDA
Medical professionals and the FDA are raising alarms over the safety and legality of compounded GLP-1 weight-loss injections.